Common Stock |
9 Months Ended |
|---|---|
Sep. 30, 2026 | |
| Equity [Abstract] | |
| Common Stock |
5. Common Stock
As of September 30, 2026, the Company has authorized 100,000,000 shares of common stock, $0.001 par value per share, and 1,000,000 shares of preferred stock, $0.001 par value per share.
The Company had 19,264,893 and 13,784,000 shares of common stock and no shares of preferred stock issued and outstanding as of September 30, 2026, and December 31, 2025, respectively.
On July 31, 2026, the Company entered into a Securities Purchase Agreement (“SPA”) with OPKO Health, Inc. (the “Purchaser”), an accredited investor, pursuant to which the Company sold and issued to the Purchaser a total of 5,474,053 shares of the Company’s common stock at a purchase price of $0.9134 per share, the Nasdaq Consolidated Bid Price on the trading day of closing, for gross proceeds to the Company of $5.0 million. No placement agent was engaged, and the Company incurred no offering costs. Dr. Phillip Frost, Chairman and Chief Executive Officer of the Purchaser, is co-founder, director and principal stockholder of the Company (see Note 8).
The holders of common stock are entitled to one vote for each share of common stock held.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure for equity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|